Transposase

Demeetra and Indiana University Biopesticide Platform Combining Gene Editing and Synthetic Biology Selected as a MDPI Journal Editor’s Choice Article

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Health, University, Genetics, Education, MDPI, Generation, Gene editing, Medicine, Saccharomyces cerevisiae, Transposase, Synthetic biology, Sterilization, RNA, Gene, Female, Indiana University, Engineering, Disease, Male, Mosquito control, Plant, Publication, Transgene, SIT, RNA interference, Therapy, Multimedia, Cas9

A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.

Key Points: 
  • A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.
  • View the full release here: https://www.businesswire.com/news/home/20240320823585/en/
    Demeetra and Indiana University research on gene edited yeast biopesticide was featured on the front cover of Fermentation.
  • According to MDPI “Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world.
  • “We wanted to engineer the ideal yeast platform for stable RNAi expression,” said Dr. Corey Brizzee, Director of Gene Editing at Demeetra.

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Webcast, Multiple myeloma, Associate, Immunomodulatory imide drug, Safety, SAN, DNA, TSCM, Prodrug, Therapy, Gene, International, CRS, Tissue, Artificial intelligence, SCR, Cytogenetics, Patient, Conference call, Blood, Haemophilia, Conference, Graft-versus-host disease, ORR, TCE, Cancer, Transposase, Partnership, Roche, Malignancy, Antibody, Neurotoxicity, Kinetics, Haemophilia A, RRMM, Cyclophosphamide, BCMA, Physician, Investigator's brochure, Bone marrow, ITT, Vanderbilt-Ingram Cancer Center, Cytokine release syndrome, Vaccine, Pharmaceutical industry, Broadcasting, Hematology

The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).
  • We are excited to have taken this first step with our early P-BCMA-ALLO1 clinical results.
  • They inspire us to further develop P-BCMA-ALLO1 in partnership with Roche, and to continue advancing our entire allogeneic TSCM cell-based CAR-T portfolio."
  • Title: Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Session Title: 704.

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

Retrieved on: 
Tuesday, May 9, 2023
Lymphoma, Amgen, Executive, Partnership, Drug development, Phenylalanine hydroxylase, Gene, CD19, Kite Pharma, Takeda, Lymphoid leukemia, CD20, Ornithine, PAH, Epithelium, Transposase, ESMO, Roche, Cancer, Breast, Oncology, Biomarker, Cell, AAV, American Society of Gene and Cell Therapy, PKU, Phenylalanine, Research and development, CAR, Development, Retirement, Genetic disorder, Novartis, Patient, Investment, SAN, Haemophilia, OTC, Mouse, Rare, European Society for Medical Oncology, Therapy, IND, News, Society, Pharmaceutical industry, Vaccine, Cryptocurrency, Research, Phenylketonuria

SAN DIEGO, May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.  

Key Points: 
  • SAN DIEGO, May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.
  • The Company currently expects to present further clinical updates for the program at a medical meeting in 2023.
  • The Company currently expects to present further clinical updates for the program at a medical meeting in 2023, subject to clearance with Roche.
  • Net loss was $38.8 million for the first quarter ended March 31, 2023, compared to $58.1 million for the same period of 2022.

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

Retrieved on: 
Sunday, December 11, 2022
Perelman School of Medicine at the University of Pennsylvania, Therapy, Genome, Security (finance), Transposase, Drug discovery, Mouse, IND, Society, Patient, Haemophilia A, Cancer, Degenerative disease, Haemophilia, Research, Roche, Coagulopathy, Factor VIII, Genetic engineering, Multimedia, University, Hospital, CHOP, SAN, ASH, Pediatrics, SPB, Vaccine, Dentistry, Takeda

SAN DIEGO, Dec. 11, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will present preclinical data from its P-FVIII-101 gene therapy program, partnered with Takeda, at the 2022 American Society of Hematology (ASH) Annual Meeting being held in New Orleans and virtually December 10–13, 2022. The data establish preclinical proof of principle for the treatment of Hemophilia A using P-FVIII-101, a non-viral liver-directed gene therapy utilizing Poseida's Super piggyBac delivery system, which could potentially lead to a functional cure. 

Key Points: 
  • The data establish preclinical proof of principlefor the treatment of Hemophilia A using P-FVIII-101, a non-viral liver-directed gene therapy utilizing Poseida's Super piggyBac delivery system, which could potentially lead to a functional cure.
  • "We are very excited by these new P-FVIII-101 data, which demonstrate normalization of FVIII levels in an animal model of Hemophilia A," said Brent Warner, President, Gene Therapy at Poseida Therapeutics.
  • "Most importantly, we have demonstrated the use of a fully non-viral gene therapy to address the underlying cause of Hemophilia A, providing key preclinical proof of principle for our program.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 8, 2022
AAV, Investor, Webcast, Company, SAN, Transposase, Therapy, Nasdaq, Genetic engineering, Multimedia, Fine chemical

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming investor conferences:

Key Points: 
  • SAN DIEGO, Nov. 8, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming investor conferences:
    Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com .
  • A replay of each webcast will be available for approximately 90 days following each presentation.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.
  • To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn .

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress

Retrieved on: 
Thursday, November 3, 2022
Security (finance), Safety, Oncology, SAN, ESMO, RRMM, U.S. Securities and Exchange Commission, Transposase, European Society for Medical Oncology, B-cell maturation antigen, Neoplasm, Genetic engineering, MUC1, 2021 Essex County Council election, Cancer, Private Securities Litigation Reform Act, Efficacy, BCMA, Patient, Epithelium, Breast, Relapse, Therapy, Multiple myeloma, Lung, Roche, Multimedia, Nasdaq, AAV, Vaccine

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

Key Points: 
  • SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.
  • The full abstracts will be made available on the ESMO website on December 1, 2022 at 12:05 AM CET.
  • Poseida has demonstrated the elimination of tumor cells to undetectable levels in preclinical models of both breast and ovarian cancer.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
SAN, LinkedIn, U.S. Securities and Exchange Commission, Lung, Society for Immunotherapy of Cancer, Therapy, SITC, Boston Convention and Exhibition Center, Patient, Genetic engineering, Twitter, Security (finance), Epithelium, Annual general meeting, Multimedia, Immunotherapy, Nasdaq, Transposase, Convention center, Private Securities Litigation Reform Act, Triple-negative breast cancer, Company, AAV, Society, Breast, Safety, Ovarian cancer, Cancer, Poster, Pharmaceutical industry, Vaccine

The poster presentation will highlight the trial design, dosing regimen, and study protocol for the Company's ongoing Phase 1 clinical trial of P-MUC1C-ALLO1.

Key Points: 
  • The poster presentation will highlight the trial design, dosing regimen, and study protocol for the Company's ongoing Phase 1 clinical trial of P-MUC1C-ALLO1.
  • The study is following a 3+3 design and is evaluating the safety, tolerability, and preliminary efficacy of P-MUC1C-ALLO1.
  • The Company expects to report initial clinical data from this trial by the end of 2022 or early 2023.
  • Poseida has demonstrated the elimination of tumor cells to undetectable levels in preclinical models of both triple-negative breast and ovarian cancer.

Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
Transposase, Therapy, SAN, LinkedIn, Genetic engineering, Conference, Nasdaq, Company, Twitter, Investor, Webcast, AAV, Fine chemical

SAN DIEGO, Sept. 7, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's Chief Financial Officer, Johanna Mylet, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022.

Key Points: 
  • SAN DIEGO, Sept. 7, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's Chief Financial Officer, Johanna Mylet, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022.
  • The on-demand session will become available at 7:00am ET on September 12, 2022.
  • A webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com .
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

Retrieved on: 
Wednesday, August 3, 2022
Twitter, U.S. Securities and Exchange Commission, Nasdaq, LinkedIn, Lymphoma, Biotechnology, ID, Private Securities Litigation Reform Act, Security (finance), Patient, IND, Transposase, Research, Genetic engineering, Therapy, AAV, Company, Multimedia, Lymphoid leukemia, Investor, Multiple myeloma, Webcast, Vaccine, Fine chemical, Pharmaceutical industry

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

Key Points: 
  • The global collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.
  • Poseida Therapeutics announces strategic global collaboration with Roche focused on #allogeneic CAR-T cell therapies.
  • "Roche is an ideal strategic partner for Poseida with its industry-leading R&D capabilities in oncology, complementary technologies and expertise, and global regulatory and commercial capabilities.
  • Working together, we look forward to advancing novel allogeneic cell therapies based upon Poseida's technologies for patients battling cancer."

Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board

Retrieved on: 
Tuesday, July 26, 2022
Helicobacter pylori, ELSI, Knowledge, Genetic engineering, NIH, Center, Industry, Twitter, U.S. Securities and Exchange Commission, National Academy of Engineering, SAN, National, Research, Transposase, Privacy, Systems biology, Genetics, OTC, Gene, Private Securities Litigation Reform Act, Achievement, George Church, National academy, Patent, Therapy, GET, Multimedia, United States Air Force Scientific Advisory Board, Human Brain Project, Intelligence, Publication, IARPA, Company, Method, Security (finance), Patient, LinkedIn, Nasdaq, Life, BRAIN, Gene editing, SAB, Regenesis, Synthetic biology, Biophysical environment, AAV, Haemophilia A, Pharmaceutical industry, Vaccine, Engineering, Science

SAN DIEGO, July 26, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D., who will serve as Chair of Poseida's newly formed Gene Therapy Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, July 26, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D., who will serve as Chair of Poseida's newly formed Gene Therapy Scientific Advisory Board (SAB).
  • "We are honored to have Dr. Church, a pioneer in the fields of genome engineering, systems biology and synthetic biology, join Poseida's Scientific Advisory Board.
  • "Dr. Church's depth of knowledge and experience, both in academia and industry, will make him a tremendous asset as Chair of our newly created Gene Therapy Scientific Advisory Board and we look forward to working with him as we build out this group of advisors."
  • "As we develop in vivo gene therapies for rare diseases in patient populations with high unmet medical need, I am thrilled to have Dr. Church lead our Gene Therapy SAB," said Brent Warner, President, Gene Therapy at Poseida.